NCT06012253

Brief Summary

The study aims to evaluate the effect of home-based walking program on peripheral neuropathy, fatigue and quality of life in patients receiving taxane and platinum-based chemotherapy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
88

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 19, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 25, 2023

Completed
21 days until next milestone

Study Start

First participant enrolled

September 15, 2023

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2024

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 20, 2024

Completed
Last Updated

June 18, 2025

Status Verified

June 1, 2025

Enrollment Period

12 months

First QC Date

August 19, 2023

Last Update Submit

June 15, 2025

Conditions

Keywords

Home-based walking programChemotherapyCancerPeripheral neuropathyFatigueQuality of lifeNurse

Outcome Measures

Primary Outcomes (5)

  • International Physical Activity Questionnaire (IPAQ- Short Form)

    It is used to evaluate physical activity. The form includes walking, moderate and vigorous activity, sitting categories. The total score includes the sum of time (minutes) and frequency (days).

    Baseline and 8th week

  • National Cancer Institute (NCI) -CTCAE v5.0 Toxicity Criteria

    This scale was developed to evaluate the grading of chemotherapy-related peripheral neurotoxicity. It evaluates sensory and motor neuropathy between grades 1-5.

    Baseline and 8th week

  • Cancer Fatigue Scale

    This scale was developed to evaluate the fatigue of cancer patients. It includes 15 questions and three sub-dimensions: Physical, Affective and Cognitive. The Likert type form is evaluated by giving points. Increasing scores received from the scale demonstrate a high level of fatigue.

    Baseline and 8th week

  • European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy (EORTC QLQ-CIPN 20)

    This scale was developed to evaluate the effect of peripheral neuropathy on quality of life of cancer patients. It includes 20 questions and three sub-dimensions: Sensory, Motor and Autonomic. The Likert type form is evaluated by giving points. Increasing scores received from the scale demonstrate a high level of symptoms and problems related to peripheral neuropathy.

    Baseline and 8th week

  • European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

    This Scale was developed to measure the quality of life of patients with cancer. It includes 30 questions and three sub-dimensions: Global health status, Functional, Symptom. High scores in the functional subscale indicate good/healthy functional status, high scores in the symptom subscale indicate high levels of symptoms and/or problems, and high scores in the global health status/quality of life subscale indicate good quality of life.

    Baseline and 8th week

Study Arms (2)

Home Based Walking Program

EXPERIMENTAL

Effect of home-based walking program on peripheral neuropathy, fatigue and quality of life

Other: Home Based Walking Program

Control group

NO INTERVENTION

The control group will be given the "Ministry of Health Physical Activity Guidelines".Routine care.

Interventions

The intervention group will be applied to "Home Based Walking Program". It was aimed that the patients should do at least 150 minutes of moderate-intensity physical exercise per week for up to 8 weeks. The content of the program includes a walking information booklet (information notes, activity chart and obstacle avoidance form), exercise diary, face-to-face-telephone counseling, sending text messages, prepared in line with international guides. It was planned to give weekly counseling to the patients included in the intervention group for an 8-week period.

Home Based Walking Program

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may not qualify if:

  • Being bone and brain metastases
  • Being peripheral neuropathy due to reasons other than chemotherapy (such as chronic disease, diabetes mellitus, nutritional disorders)
  • Skin sensitivity on the hands and feet
  • Having cardiovascular, pulmonary, musculoskeletal, or psychological disorders that limit exercise or mobility
  • Being in another supportive program
  • Being in the very active category according to the "International Physical Activity Scale (IPAQ- Short Form)"
  • Being a severity of more than 4 points according to the "Modified Borg Scale (MBS)"
  • Being a score of 2 and above according to the "ECOG Performance Scale"

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Akdeniz University

Konyaalti, Antalya, 07058, Turkey (Türkiye)

Location

MeSH Terms

Conditions

NeoplasmsPeripheral Nervous System DiseasesFatigue

Condition Hierarchy (Ancestors)

Neuromuscular DiseasesNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Fatma Arikan, PhD, RN

    Akdeniz University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
Single Blind (Participant, Outcomes Assessor)
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: This is a randomized controlled trial consisting of two groups: experimental and control
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

August 19, 2023

First Posted

August 25, 2023

Study Start

September 15, 2023

Primary Completion

August 30, 2024

Study Completion

December 20, 2024

Last Updated

June 18, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations